fbpx
Sign up now!
Don't show this again
Download the report!Continue to Site >
or wait 7 secs

Thank you for confirming your subscription!

(And remember, if ever you want to change your email preferences or unsubscribe, just click on the links at the bottom of any email.)

We’re glad you’re enjoying Pig Health Today.
Access is free but you’ll need to register to view more content.
Already registered? Sign In
Tap to download the app
X
Share
X

REPORTS

Collect articles and features into your own report to read later, print or share with others

Create a New Report

Favorites

Read Later

Create a new report

Report title (required) Brief description (optional)
CREATE
X
NEXT
PORK POULTRY
follow us


You must be logged in to edit your profile.

Favorites Read Later My Reports PHT Special Reports
Pig Health Today is equipped with some amazing (and free) tools for organizing and sharing content, as well as creating your own magazines and special reports. To access them, please register today.
Sponsored by Zoetis

Pig Health Today | Sponsored by Zoetis

.

Pigs vaccinated with Fostera®PCV MH equally protected, weighed nearly 8 pounds more in large comparison trial

Download the PDF

Pigs vaccinated with Fostera® PCV MH were equally protected against porcine circovirus (PCV) type 2d as well as Mycoplasma hyopneumoniae (M. hyo) and weighed 7.78 pounds more than pigs vaccinated with Circumvent® PCV-M G21 in a trial involving 550 pigs.2

“Pigs that received two doses of Fostera PCV MH had significantly better average final weight — 257.78 pounds — and average daily gain (ADG) compared to the Circumvent group,” said Lucina Galina, DVM, PhD, director of swine technical services, Zoetis (Figure 1). They also weighed nearly 16 pounds more than unvaccinated controls, again a significant difference.

The next best final average weight and ADG were among pigs in the one-dose Fostera PCV MH group. These results were numerically better than results in the Circumvent PCV-M G2 group and a third group vaccinated with CircoFLEX® and MycoFLEX®.3

Blind study

For the study, commercial pigs were raised in a commercial-like environment. The pigs had two prevalent influenza subtypes (H1N2, H3N2) and Streptococcus suis, not an uncommon field scenario, Galina said of the Zoetis-sponsored study, conducted at a Midwest contract research facility.

Investigators distributed pigs from multiple litters into groups of 110. Pigs from each litter were represented in every group, which received one of five treatments per label directions:

  • 1-ml dose of Fostera PCV MH at 3 and 5 weeks of age
  • 2-ml dose of Fostera PCV MH at 3 weeks of age
  • 1-ml dose of Circumvent PCV-M G2 at 3 days of age and 3 weeks later
  • 1-ml dose of Ingelvac CircoFLEX plus 1-ml dose of Ingelvac MycoFLEX at 3 weeks of age
  • 1-ml dose of saline at 3 and 5 weeks of age (control group)

Severe challenge

At 8 weeks of age, researchers challenged pigs with M. hyo and, 1 week later, with a high, intranasal and intramuscular dose of PCV2d, the most predominant PCV genotype based on sequencing of samples submitted to Iowa State’s Veterinary Diagnostic Laboratory.4 Investigators tracking results did not know which treatment each group received.

All three vaccines controlled PCV viremia well, based on cycle-threshold values, compared to unvaccinated, challenged controls. “This clearly demonstrated that one- or two-dose regimens of Fostera PCV MH are as effective as its competitors,” she said.

Injection-site reactions were negligible, Galina added, and there were no significant differences among vaccine groups based on immunohistochemistry, an indicator of virus in lymph nodes.

Fewer gross lesions

At 12 weeks of age, investigators examined 24 pigs from each group for gross lung lesions. Pigs in both Fostera PCV MH groups and the Circumvent PCV-M G2 group had significantly (p<0.05) lower lesion scores than the CircoFLEX plus MycoFLEX group.

Galina noted that Zoetis recently increased the PCV-antigen level in Fostera PCV MH and that the MetaStim® adjuvant in Fostera PCV MH helps pigs mount a strong, cell-mediated immune response.5

“These recent study results demonstrate that Fostera PCV MH can provide pork producers with an effective and safe option for managing PCV in their herds,” she said.

 

Click figure to enlarge

 

 

 

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. 


1 Circumvent PCV-M G2 is a Merck Animal Health product.
2 Data on File, Study Report No. 16PRGBIO-01-01, Zoetis LLC.
3 Ingelvac CircoFleX and ingelvac mycoFleX are Boehringer Ingelheim products.
4 Xiao C-T, et al. PCV2d-2 is the predominant type of PCV2 CNa in pig samples collected in the us during 2014-2016. Vet Microbiol. 2016 dec;197:72-77.
5 Seo HW, et al. comparative analyses of humoral and cell-mediated immune responses upon vaccination with different commercially available single-dose porcine circovirus type 2 vaccines. Res Vet Sci. 2014;97:38-42.

 

 

DISCOVERIES, Issue 1
Discoveries is a series of  research news reports written by the editors of Pig Health Today on behalf of the US Pork Business of Zoetis.

FST-00033
September 2017




Posted on March 21, 2018

tags: , , , ,
RELATED NEWS



You must be logged in to edit your profile.

Google Translate is provided on this website as a reference tool. However, Poultry Health Today and its sponsor and affiliates do not guarantee in any way the accuracy of the translated content and are not responsible for any event resulting from the use of the translation provided by Google. By choosing a language other than English from the Google Translate menu, the user agrees to withhold all liability and/or damage that may occur to the user by depending on or using the translation by Google.